Table 2:
Immune response for poliovirus types 1, 2, and 3 by study group in the modified intention-to-treat population
nOPV2 only group (n=244) | nOPV2 plus bOPV group (n=246) | bOPV only group (n=246) | |
---|---|---|---|
| |||
Poliovirus type 1 | |||
Immune response at the age of 10 weeks after one dose | 2 (1%; 0–3) | 191 (78%; 72–83) | 193 (78%; 73–83) |
Cumulative immune response by the age of 14 weeks after two doses | 10 (4%; 2–7) | 227 (92%; 88–95) | 229 (93%; 89–96) |
Cumulative immune response by the age of 18 weeks after three doses | 20 (8%; 5–12) | 240 (98%; 95–99) | 240 (98% [95–99) |
Poliovirus type 2 | |||
Immune response at the age of 10 weeks after one dose | 156 (64%; 58–70) | 72 (29%; 24–35) | 0 (0%; 0–2) |
Cumulative immune response by the age of 14 weeks after two doses | 209 (86%; 81–90) | 159 (65%; 58–70) | 5 (2%; 1–5) |
Cumulative immune response by the age of 18 weeks after three doses | 225 (92%; 88–95) | 193 (78%; 73–83) | 20 (8%; 5–12) |
Poliovirus type 3 | |||
Immune response at the age of 10 weeks after one dose | 3 (1%; 0–4) | 160 (65%; 59–71) | 148 (60%; 54–66) |
Cumulative immune response by the age of 14 weeks after two doses | 6 (2%; 1–5) | 216 (88%; 83–91) | 212 (86%; 81–90) |
Cumulative immune response by the age of 18 weeks after three doses | 8 (3%; 2–6) | 233 (95%; 91–97) | 231 (94%; 90–96) |
Data are the number of vaccine responders (% [95% CI]). bOPV=bivalent oral poliovirus vaccine. nOPV2=novel oral poliovirus vaccine type 2.